AbbVie’s Reports Results of Rinvoq (upadacitinib) in P-III (U-EXCEED) Induction Study for the Treatment of Crohn's Disease
- The P-III (U-EXCEED) induction study evaluates upadacitinib (45mg, qd) vs PBO in adults with mod, to sev. CD who had inadequately responded to or were intolerant of biological therapy
- The trial meet both 1EPs of clinical remission & endoscopic response @12wks., a greater proportion of patients achieved steroid-free clinical remission & endoscopic response @12wks. safety results were consistent with the known profile of upadacitinib & no new safety risks were observed
- Additionally, similar results were seen with clinical remission per SF/AP (40% vs 14%), improvement in intestinal mucosa by endoscopy, improvement in early symptom @2wks. along with clinical remission @4wks.
Ref: AbbVie | Image: abbvie
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com